Ivosidenib – Targeted Mutant IDH1 Inhibitor Therapy
Ivosidenib is an oral, potent, first-in-class small-molecule inhibitor of the mutant isocitrate dehydrogenase-1 (IDH1) enzyme. The drug was developed for the precision targeted therapy of hematologic malignancies and certain solid tumors characterized by specific somatic mutations in the IDH1 gene (specifically replacing the arginine amino acid at position R132). Normally, the wild-type IDH1 enzyme catalyzes the conversion of isocitrate to alpha-ketoglutarate. The mutant form of IDH1 acquires an aberrant neomorphic activity and begins reducing alpha-ketoglutarate into the oncometabolite R-2-hydroxyglutarate (2-HG). Accumulation of 2-HG leads to epigenetic DNA hypermethylation, blockade of cellular differentiation, and induces leukemogenesis or oncogenesis. The mechanism of action of ivosidenib involves selective binding to and inhibition of the mutant IDH1 dimer, thereby reducing 2-HG levels in plasma and bone marrow cells, restoring normal differentiation of immature myeloid cells.
The clinical uniqueness of ivosidenib lies in the fact that it is not a traditional cytotoxic chemotherapeutic drug, but acts as a pro-differentiating agent. Under its influence, aberrant blast cells cease uncontrolled proliferation, mature into functional mature neutrophils and monocytes, and die through natural apoptotic pathways. This property makes it irreplaceable in treating a subgroup of patients with acute myeloid leukemia (AML) and cholangiocarcinoma harboring a confirmed IDH1 R132 mutation. The drug is well absorbed following oral administration, exhibits a prolonged elimination half-life (approximately 72–93 hours), is metabolized primarily in the liver via the cytochrome CYP3A4 isoenzyme, and is excreted predominantly in the feces as unchanged drug and metabolites.
The drug is administered orally. Prior to initiating therapy, confirmation of the IDH1 R132 mutation using validated companion diagnostic testing is mandatory. Continuous clinical monitoring via electrocardiograms and complete blood counts is required during treatment.
Indications
Ivosidenib is indicated for the targeted treatment of adult patients with the following malignancies:
- Acute Myeloid Leukemia (AML): in combination with azacitidine or as monotherapy for the treatment of newly diagnosed AML with an IDH1 R132 mutation in adult patients who are ≥75 years old or who have comorbidities that preclude use of intensive induction chemotherapy.
- Relapsed or Refractory AML: as monotherapy for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with a confirmed IDH1 R132 mutation.
- Cholangiocarcinoma: as monotherapy for the treatment of locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation in previously treated adult patients whose disease has progressed following at least one prior line of systemic therapy.
Dosage and administration
The dosing regimen of ivosidenib is continuous and based on a standard daily dose administered with careful attention to treatment tolerability.
- Standard Dose: the recommended therapeutic dose is 500 mg taken orally once daily.
- Schedule: the drug is administered daily without scheduled rest periods. A conventional treatment cycle constitutes 28 days. Therapy should be continued until disease progression or unacceptable systemic toxicity occurs.
- Administration Method: tablets are swallowed whole at approximately the same time each day, with or without food (except for high-fat meals, which significantly increase absorption). Administer with water; do not break, crush, or chew the tablets.
- Missed Dose: if a dose is missed and less than 12 hours have passed, the patient should take the missed dose immediately. If more than 12 hours have passed, the dose should be skipped, and the regular daily schedule resumed the following day.
- Dose Modification: if the QTс interval prolongs beyond 500 ms, ivosidenib should be withheld until the interval recovers. In the event of severe Differentiation Syndrome, immediate corticosteroid therapy must be initiated, and ivosidenib temporarily withheld if clinically indicated.
